Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot!
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope and Dr. Jonathan Kay discuss the Great Debate, which Dr. Pope participated in, at ACR22 Convergence in Philadelphia, PA.
Watch video →
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at ACR22 Convergence. Abstract 0793: Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation Abstract L08: Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Watch video →
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at ACR22 Convergence.
Watch video →
Switch vs Cycle in PsA
Dr. Arthur Kavanaugh discusses abstract 1600 at ACR22 Convergence. Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Watch video →
New Treatments for SLE?
Dr. Michelle Petri discusses abstract 1117 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1117: Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Watch video →
Best of PsA on Day 1
Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence. Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Watch video →
Urinary Biomarkers in Lupus
Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Watch video →
A Novel Treatment Response Measurement Tool for Lupus
Dr. Kathryn Dao discusses abstract 2054 with Dr. Eric Morand at the ACR22 Convergence meeting. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process.
Watch video →
Dr. Antoni Chan synovialjoints
3 years 10 months ago
Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors, ≥ 65 years 6%–23%. Rates of adjudicated MACE and VTE with UPA were infrequent, consistent with background rates in RA, PsA, and AS Abst 0510 https://t.co/HDkQ6ELnAy #ACR22 @RheumNow https://t.co/SRJYdFFNIQ
Dr. Antoni Chan synovialjoints
3 years 10 months ago
New concept of sJIA to MAS as a continuum on the spectrum of disease severity. Molecular basis via impact of mTORC1 (mechanistic target of rapamycin complex 1) inhibition in Il1rn-/- mice. Looking forward to the full paper. Huang Z Abs004 https://t.co/3OtIp90PnG #ACR22 @RheumNow https://t.co/PPHQj8bYKu
sheila RHEUMarampa
3 years 10 months ago
How can we differentiate statin-assoc autoimmune necrotizing myopathy from toxic statin #myopathy?🔎
Remember this important slide👇
#ACR22 @Rheumnow #acrreview https://t.co/hKMJuGDJWt
sheila RHEUMarampa
3 years 10 months ago
Statin therapy may exacerbate underlying neuromuscular disorders.
‼️REMEMBER☝️The only ABSOLUTE contraindication to statins are pts who are HMGCR+
#ACR22 @RheumNow #acrreview https://t.co/A3XGHlrm0X
sheila RHEUMarampa
3 years 10 months ago
Interesting study by Dr Ai Li Yeo and colleagues on repetitive anti-dsDNA testing and flare prediction:
🔅Fluctuations (⬆️and ⬇️) in anti-dsDNA >2 fold was assoc'd w/⬆️flares in all groups including persistently + pts.
#ACR22 @RheumNow ABST#327 https://t.co/q0WXnIwV4A
sheila RHEUMarampa
3 years 10 months ago
In this study, Dr. Niti Goel shows the under-reporting of race & ethnicity in publications of #psoriaticarthritis clinical trials
🧐Participant diversity is important to consider since different races & ethnicities may respond differently to therapies
#ACR22 @RheumNow ABST0090 https://t.co/BzHpuHYVI5
sheila RHEUMarampa
3 years 10 months ago
Post hoc analysis from the SELECT-PsA 1 trial by Dr. @DrLauraCoates and team:
💊Pts on UPA showed greater improvement from BL in RAPID3 vs. ADA in all visits
💊Pts on UPA had better responses in all assessments vs. PBO
Reassuring data. #ACR22 @RheumNow ABST0192 https://t.co/NgeUU5bPPf
Akhil Sood MD AkhilSoodMD
3 years 10 months ago
Abstr 0383 evaluated the use of previously developed AI algorithm to detect sacroiliitis in a new axSpA cohort. The neural network achieved
-Sensitivity 82%; specificity 81%
-PPV 0.89; NPV 0.70
https://t.co/PDSsiMIQUc
@RheumNow #ACR22 #AI #MachineLearning #AxSpA https://t.co/mXUHUowGhQ
Akhil Sood MD AkhilSoodMD
3 years 10 months ago
Abstr #0195 examined acceptance of Virtual Reality among pts w/ rheumatic diseases (RD)
- VR naïve & experienced were willing to use VR to manage their RD
- VR experienced pts had ↑ % of perceived usefulness & anticipated enjoyment of VR in dx and mgmt of RD
@RheumNow #ACR22 https://t.co/r7X8Kqp8UN
Eric Dein ericdeinmd
3 years 10 months ago
Abst0338 #ACR22 Transition from CLE to SLE
324 cases of incident cutaneous lupus, mean f/u 8 years
26 pts developed SLE. 5.2% transition by 5 years, <3% risk every 5 yrs from 5-20 years
Risk factors: SCLE, younger age, recent diagnosis
@RheumNow #ACRBest https://t.co/JFcUIkfA9n
Eric Dein ericdeinmd
3 years 10 months ago
Year in Review #ACR22
Pre-expos PPx for COVID!
Tix-Cil (Evusheld): risk reduction 77%
Cardiac AES 0.6% vs placebo 0.2%
Only 3.3% were on immunosuppression
But Israeli study with immunosuppressed:
92% half as likely to be hospitalized or die
1/2 less infections
@RheumNow
Eric Dein ericdeinmd
3 years 10 months ago
Ab1291 #ACR22: 🔥Ignite🔥
@DavidLeverenz: Constructed a model to identify telehealth visits - PPV 0.8, sensitivity 0.39 - better than existing practice (PPV 0.77)
Predictors: age, diagnoses, medications, RAPID3, provider preference for 💻🩺
3 mo pilot program predictive
@RheumNow https://t.co/Iey87SVGv4
Robert B Chao, MD doctorRBC
3 years 10 months ago
Very important point about statin induced myopathy by Dr. Christopher-Stine.
If 1) history of statin exposure, 2) typical symptoms of myositis 3) HMGCR ab positive — do NOT need biopsy and can treat as statin associated necrotizing autoimmune myopathy!
@RheumNow #ACR22 https://t.co/VHxPRkCWwj
Dr. Rachel Tate uptoTate
3 years 10 months ago
Among ANCA-vasculitis hospitalizations, A Fib found to be most common CV condition. Females had fewer CV complications, lower in-hospital mortality & shorter length of stay compared to males. Abs 0434 #ACR22 https://t.co/2IikApUdvE https://t.co/16ggVScs3a
Dr. Rachel Tate uptoTate
3 years 10 months ago
SELECT-AXIS 2 subgroup analysis. UPA demonstrated improved efficacy vs PBO at Wk 14 across all evaluated subgroups of pts with bDMARD-IR AS. No new safety signals. @XBaraliakos et al, Abs 0414 #ACR22 https://t.co/lTfm68XlEY https://t.co/PaWdrOljMO
